focus -WSS

focus

author：entertainment 2025-10-01 18:07:38 - browse：2831

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Deliver public health messages at the right time

WSS

Cheap, fast test for Zika and dengue could cost just $1

'Essentially witchcraft:' A former naturopath takes on the field

Moderna says combo Covid

PBM executives asked to testify by House panel

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Black vets could get higher VA benefits if race not used in lung test

entertainment

focus

focus

Medicare proposal to cover medical devices draws a mixed reaction

Coercive sterilizations revealed by STAT prompt outrage

Activists slam private health insurers over coverage restrictions

Crowdfunding for medical bills sidesteps core problem, author says

Hepatitis C has a cure — but many Americans still lack access to it

Novel spinal cord stimulator treats paralysis without surgery

Medicare proposal to cover medical devices draws a mixed reaction

Health care court cases: Humana, Sutter, Novant

Novavax promises a turnaround & Lilly roils the obesity market

How a small hospital in rural Puerto Rico survived Hurricane Maria

focus

Pharma companies must ensure equitable access to obesity drugs

Primary care doctor shortage won't be solved by free med school tuition

Cheap, fast test for Zika and dengue could cost just $1

Lawmakers grill UnitedHealth CEO on Change cyberattack

Black vets could get higher VA benefits if race not used in lung test

Novel spinal cord stimulator treats paralysis without surgery

focus

hotspot

knowledge

hotspot